ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olomorasib

Also written as “Olomorasib”, “LY3537982” and “[¹⁴C]-LY3537982”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Renal Insufficiency · Hepatic Insufficiency, led by 3 companies.

Drug pageOlomorasib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 1, 202316 company-led studies, 7 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only145 open or runningphase 3since Nov 1, 2023Jul 2, 2021Apr 2027phase 2 · NCT04956640
Daiichi Sankyoits history only11 open or runningphase 2since Oct 16, 2026Oct 16, 2026Sep 30, 2029phase 2 · NCT07890714
Johnson & Johnson11 open or runningphase 2since Nov 10, 2025Nov 10, 2025Nov 30, 2028phase 2 · NCT07227025
  • Named in Eli Lilly’s own pipeline as Olomorasib, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: AstraZeneca and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024Named olomorasibINNProposed as its International Nonproprietary Name in WHO's List 131 · before, LY3537982
  2. Nov 10, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07227025 · 60 planned · United States, Canada, China and more

Ahead

  1. Nov 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07227025

TargetBeta

“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, …”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

The one study Johnson & Johnson leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07227025Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more2RecruitingNov 30, 202860

How it is read

Names in the registry

  • “Olomorasib”, 8 entries
  • “LY3537982”, 7 entries
  • “[¹⁴C]-LY3537982”, 2 entries
  • “Olomorasib test”, 1 entry
  • “Olomorasib reference”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.